CD133+ has been utilized to identify a radioresistant subpopulation of glioma cells, demonstrating that radioresistance increased DNA repair in glioblastoma CSCs and pointing to the expression of CD133 as a prediction factor of clinical outcomes for patients with glioma [133]. This evidence concerns the gene PROM1 and glioma.